Filter posts

John Lechleiter Forbes Op-Ed: Debunking the Five Big Myths About 'Big Pharma'

This week, Eli Lilly and Company President, Chairman and CEO John Lechleiter refutes five big …

More Than 90 Patient Organizations Urge Congress to Protect Patients and Innovation

Today, the Epilepsy Foundation and a diverse group of more than 90 advocacy organizations submitted …

BIO Applauds Energy and Commerce Health Subcommittee for Approving 21st Century Cures Act

Today, the Biotechnology Industry Organization (BIO) praises the Energy and Commerce Health Subcommittee for approving …

TSC Global Awareness Day

On May 15, the Tuberous Sclerosis Alliance (TS Alliance) will join tuberous sclerosis complex (TSC) …

Jim Greenwood in New York Times: Specialty Tiers Limit Patient Access

Today, the New York Times published a letter from Jim Greenwood, BIO’s President and CEO. …

Tick Size Pilot Program: A Few Pennies Make a Big Difference

Earlier this week, the Securities and Exchange Commission (SEC) approved a tick size pilot program …

United Health To Congress: Let Cancer Patients Eat Gauze (Op-Ed in The Hill)

Jonathan Wilcox’s op-ed in The Hill today highlights the growing challenge of insurance company tactics that …

April is Donate Life Month! Walk with the National Kidney Foundation on May 16!

The need for organ donations continues to increase in America. Of the over 123,600 Americans …

The Power of Innovation

Today’s “Fox and Friends” included an informative segment about the staggering advances being made in …

BIO Principles on Expanded Access to Investigational, Unapproved Medicines

Seriously ill patients with limited or no alternative therapies, and who are ineligible or unable …